Table 2 ADCs investigated in clinical trials for pancreatic cancer
From: Antibody drug conjugates: hitting the mark in pancreatic cancer?
Trial Number | Phase | ADC name | Target | Linker | Payload | Status |
|---|---|---|---|---|---|---|
ADC Monotherapy | ||||||
NCT05043987 | Phase I | CPO102 | Claudin 18.2 | Cleavable | MMAE (auristatin) | Not yet recruiting |
NCT05525286 | Phase I/II | SOT102 | Claudin 18.2 | Non-cleavable | Anthracycline PNU159682 | Recruiting |
NCT05156866 | Phase I | TORL-2-307-ADC | Undisclosed | Undisclosed | Undisclosed | Recruiting |
NCT05498597 | Phase I | AMT-151 | Folate Receptor alpha | Undisclosed | Undisclosed | Recruiting |
NCT04659603 | Phase II | Tusamitamab Ravtansine | CEACAM5 | Cleavable | DM4 (maytansinoid) | Recruiting |
NCT03602079 | Phase I/II | A166 | HER2 | Cleavable | Duo-5 (anti-microtubule agent) | Active, not recruiting |
NCT01631552 | Phase I/II | Sacituzumab Govitecan-hziy | Trop-2 | Cleavable | SN-38 (topoisomerase I inhibitor) | Completed |
NCT01166490 | Phase I | ASG-5ME | SLC44A4 | Cleavable | MMAE (auristatin) | Completed |
NCT03023722 | Phase II | Anetumab Ravtansine | Mesothelin | Cleavable | DM4 (maytansinoid) | Completed |
NCT02999672 | Phase II | Trastuzumab Emtansine | HER2 | Non-cleavable | DM1 (maytansinoid) | Completed |
NCT01577758 | Phase I | TAK-264 (MLN0264) | GCC | Cleavable | MMAE (auristatin) | Completed |
NCT02202785 | Phase II | TAK-264 (MLN0264) | GCC | Cleavable | MMAE (auristatin) | Terminated |
NCT03449030 | Phase I | TAK-164 | GCC | Cleavable | DGN549 (DNA alkylating agent) | Terminated |
NCT02908451 | Phase I | AbGn-107 | AG7 antigen | Proprietary linker | DM4 (maytansinoid) | Terminated |
ADC in combination with oral PARP inhibitor AZD5305 | ||||||
NCT04644068 | Phase I/II | Trastuzumab Deruxtecan Datopotamab Deruxtecan | HER2 Trop2 | Cleavable | Deruxtecan (topoisomerase I inhibitor) | Recruiting |
ADC in combination with checkpoint inhibition | ||||||
NCT05293496 | Phase I | MGC018 | B7-H3 | Cleavable | Duocarmycin analog | Recruiting |
NCT04925284 | Phase I | XB002 | Tissue factor | Proprietary linker | ZymeLink Auristatin | Recruiting |
NCT03816358 | Phase I | Anetumab Ravtansine | Mesothelin | Cleavable | DM4 (maytansinoid) | Active, not recruiting |